Studies have found that cationic micelle delivery of multi-epitope candidate vaccines derived from tumor-associated antigens (including PIK3CA) can lead to regression of established CT26 colon tumors in mice (Sabzehei et al., 2023). The gene discussed is PIK3CA; the disease is neoplasm.